David Hundertmark1, Benjamin Bender1, and Uwe Klose1
1Diagnostic and Interventional Neuroradiology, University Hospital Tuebingen, Germany, Tuebingen, Germany
Synopsis
In
MR-spectroscopy of gliomas, sometimes an elevation of the signal at 3.55 ppm at
an echo time of 135 ms is found, which can be interpreted as myo-inositol or as
glycine. Due to coupling effects, the signal of inositol should be reduced at
an echo time of 90 ms, while the glycine signal should be larger than at TE 135
ms. In measurements of glioma patients, which show an enhanced signal at 3.55
ppm at TE 135ms, we found a decreased signal at TE 90. Therefore, we saw no
indication of elevated glycine concentration in gliomas.
Introduction
Magnetic-resonance-spectroscopy
(MRS) allows the detection of several metabolites (e.g. N-acetylaspartate (NAA),
Choline (Cho), Creatinine (Cr), myo-inositol (Ins) and Glycine (Glyc). In
glioma the concentration of these metabolites changes compared to healthy brain
tissue. One metabolite, which has been in focus of research over the last years,
is Glyc. Its two protons produce a singlet signal at 3.55 ppm [1],
which is subject to a continuous decrease over time (T2 decay). Glyc is often reported to be an elevated
metabolite in glioma. [2, 3] Its signal is overlapped by the more intense
signal of myo-inositol (Ins), making accurate detection difficult. The Ins
signal consists of a triplet-like structure and a doublet of doublets [4]. These coupling effects lead to a loss of the
Ins signal between 60-100ms TE in the spin-echo sequence (SE) [5]. Today,
the usage of spin-echo sequence in clinical settings is slowly replaced by the
semilaser sequence (sLaser).
Therefore,
the purpose of this study was exploring the described loss of signal in sLaser
and furthermore investigating the signal at 3.55 ppm in glioma-patients showing
elevated signals in standard diagnostic spectroscopy.Material and Methods:
In a first step 5 healthy subjects (3
female, 2 male) were recruited for a prospective MR-study. Measurements were
performed on a 3T-MR-Scanner, using a 64-channel-headcoil. T2-weighted
sequences were used to plan the spectroscopy. For 5 subjects sLaser with 16x16
matrix, each voxel being 1*1*1,5 cm, was used. Spectroscopy was acquired at 40-130
ms TE in increments of 10 ms in the region above the corpus callosum.
The signal of the inner 8x8 voxels was averaged using Mat-Lab and plotted
against TE. TE_min was defined as the TE where the area under the curve of the
Ins signal reaches zero.
TE_min was then applied in patients.
In a second step glioma patients with an
enhanced signal at 3.55 ppm were recruited (up to now n=3).
sLaser spectroscopy was acquired at 135 ms (standard in our hospital) and TE_min
ms for Patient 1 and Patient 2. Patient 3 was also measured at 40 ms TE. The
signal was again plotted with Mat-Lab in tumorous voxels.
Results:
In the sLaser in healthy subjects, we saw
a decrease of the signal at 3.55 ppm over TE. Between 90ms and 110 ms no signal
was detected, followed by a renewed rise starting from 110 ms TE. Meanwhile the
signal of other important metabolites as NAA, Cho and Cr showed approximately a
continuous decrease. (Figure 1) Therefore TE_min was selected as 90 ms.
In all three patients we saw a smaller signal at 3.55 ppm at TE_min than in the
135ms TE. The Signal of Cho and Cr showed again a decrease over time. (Figure
2, 3)Discussion
The loss of signal at 3.55 ppm described for SE could be found slightly
shifted in sLaser, too. This effect could be therefore used to improve the
detection of Glyc with sLaser. The reason for the different behaviour could be
the more complex excitation pulses of sLaser.
In our patients we found a smaller signal at 3.55 ppm at TE_minthan at 135 ms
TE. The signal course is therefore similar to that of Ins that we have seen in healthy
subjects. We conclude that in our patients the increase of the signal at 3.55
ppm at 135 ms TE is not due to an increased Glyc concentration. This contradicts
the thesis that enhanced signal in 3.55 ppm in 135 ms TE is assigned as elevated
Glyc concentration. One possible reason for the increased signal at 3.55 ppm at
135ms TE might be elevation of concentration of Ins. Both, an elevated
concentration of total Ins or just the effect of a shift of Ins in the extracellular
space due to low pH in the glioma microenvironment, represent potential
explanations.[6]Conclusion:
In contrast to previous studies, our results indicate that the signal
augmentation at 3.55 ppm at 135ms TE in glioma is caused by Ins. It would be
therefore interesting to investigate more patients to confirm these results. In
the future this could lead to a differentiation of subgroups, which will be
then studied as predictor for tumor grade.Acknowledgements
IZKF scholarship of the medical faculty of Tuebingen
References
1. Gambarota, G., et
al., In vivo 1H NMR measurement of
glycine in rat brain at 9.4 T at short echo time. Magnetic Resonance in
Medicine, 2008. 60(3): p. 727-731.
2. Tiwari, V., et
al., Measurement of glycine in healthy
and tumorous brain by tripleārefocusing MRS at 3 T in vivo. NMR in
Biomedicine, 2017. 30(9): p. e3747.
3. Hattingen, E., et
al., 1H MR spectroscopic imaging with
short and long echo time to discriminate glycine in glial tumours. Magnetic
Resonance Materials in Physics, Biology and Medicine, 2008. 22(1): p. 33.
4. Cerdan, S., et
al., Nuclear magnetic resonance
spectroscopic analysis of myo-inositol phosphates including inositol
1,3,4,5-tetrakisphosphate. J Biol Chem, 1986. 261(31): p. 14676-80.
5. Maudsley, A.A.,
et al., Mapping of Glycine Distributions
in Gliomas. American Journal of Neuroradiology, 2014. 35(6 suppl): p. S31-S36.
6. Charlotte Stagg,
D.L.R., Magnetic Resonance Spectroscopy -
Tools for Neuroscience Research and Emerging Clinical Applications 2014:
Academic Press Inc, pages 122-124.